| Mrs Jane M Wappelhorst, CNM | |
|
2200 W Hamilton St, Suite 212, Allentown, PA 18104-6337 | |
| (610) 435-8130 | |
| (610) 435-4515 |
| Full Name | Mrs Jane M Wappelhorst |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 2200 W Hamilton St, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356336598 | NPI | - | NPPES |
| 0014535750004 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | MW008353-L (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Jane M Wappelhorst, CNM 2200 W Hamilton St, Suite 212, Allentown, PA 18104-6337 Ph: (610) 435-8130 | Mrs Jane M Wappelhorst, CNM 2200 W Hamilton St, Suite 212, Allentown, PA 18104-6337 Ph: (610) 435-8130 |
News Archive
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).
VOA News examines the ethics of conducting clinical drug trials in developing countries, particularly in Africa. Several international ethical frameworks outline guidelines for clinical trials, "including the World Medical Association's Declaration of Helsinki and the WHO's Good Clinical Practice Guidelines," but they are not mandatory, the news service writes.
Using a specially designed risk assessment tool within 24 hours of admission was an effective way of identifying which hospital patients in medical and surgical units would become violent. Researchers studied more than 2,000 patients admitted to an acute care hospital over a five-month period. As well as identify the traits that were most likely to lead to violence, they found that a disproportionate number of elderly patients and males became violent.
Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).
› Verified 2 days ago
Mrs. Laurice S Dunning, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 2200 W Hamilton St, Suite 212, Allentown, PA 18104 Phone: 610-435-8130 Fax: 610-435-4515 | |
Honi Trauger, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1611 Pond Rd Ste 300, Allentown, PA 18104 Phone: 610-398-7700 | |
Ms. Christina Louise Felten, MSN,CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 1611 Pond Rd, 401, Allentown, PA 18104 Phone: 610-398-7700 Fax: 610-398-6913 | |
Nissa J Gossom, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 1611 Pond Rd, Suite 401, Allentown, PA 18104 Phone: 610-398-7700 | |
Cynthia Dinsmore, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 1627 W Chew St, Allentown, PA 18102 Phone: 610-402-1600 Fax: 610-969-2197 | |
Erika Keller, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 610-402-8510 |